BOUL Boule Diagnostics AB (publ)

0.1216USD1.235 SEK · STO+2.49%Mkt Cap: 4.72M USDP/E: —

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and …

Institutional holders1 on file

Key Statistics

Company
Market Cap4.72M USD
Enterprise Value24.70M USD
Revenue (TTM)42.35M USD
Gross Profit21.05M USD
Net Income (TTM)-369.41K USD
Revenue/Share1.09 USD
Last Price0.1216 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees200
CountrySE
SectorHealthcare
IndustryMedical Devices
ISINSE0011231158
Valuation
P/E (Trailing)—
P/E (Forward)1.09
PEG—
EV/EBITDA20.65
EV/Revenue0.58
P/S0.11
P/B0.29
EPS (TTM)-0.04 USD
EPS (Forward)0.11 USD
52W Range
0.08277% of range0.6162
52W High0.6162 USD
52W Low0.0827 USD
Profitability
Gross Margin43.66%
Oper. Margin2.40%
EBITDA Margin2.83%
Profit Margin-0.77%
ROE-2.24%
ROA-0.80%
ROIC6.53%
ROCE18.48%
Growth
Revenue Growth-24.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF81.60K USD
CapEx (TTM)488.51K USD
FCF Margin2.20%
FCF Yield19.70%
Net Debt19.98M USD
Net Debt/EBITDA16.70
Net Debt/FCF21.48
Balance Sheet
Debt/Equity1.33
Current Ratio0.92
Quick Ratio0.57
Book Value/Sh0.42 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield0.52%
Payout Ratio0.00%
Ex-Div DateMay 6, 2022
Pay Date—
Splits
Last Split4:1
Split DateJun 1, 2018
Analyst Consensus
Rating—
Target (Mean)0.3740 USD
Upside (mean)+207.7%
Target Range0.3740 USD – 0.3740 USD
# Analysts1
Ownership
Shares Out.38.83M
Float22.80M
Insiders35.31%
Institutions35.65%
Technical
SMA 500.1872 (-35.0%)
SMA 2000.3169 (-61.6%)
Beta0.32
S&P 52W Chg12.00%
Avg Vol (30d)664.93K
Avg Vol (10d)604.28K
Technical Indicators
RSI (14)39.8
MACD-0.1936
MACD Signal-0.2496
MACD Hist.+0.0560
BB Upper0.1665 USD
BB Middle0.1199 USD
BB Lower0.0733 USD
BB Width77.74%
ATR (14)0.0206 USD
Vol Ratio (20d)0.12x

About Boule Diagnostics (STO: BOUL)

›

Boule Diagnostics (STO: BOUL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 200 employees.

The shares were at 1.235 SEK on 19 November 2026, down 79.4% over 52 weeks. Its 52-week range is 0.8400 SEK to 6.260 SEK: the price is 80.3% below the high and 47.0% above the low.

Its market capitalisation is 47.96M SEK.

Boule Diagnostics reports return on equity of -2.2%, an operating margin of 2.4% and revenue down 24.4% year over year.

Its debt exceeds its cash by 203.00M SEK, a debt-to-equity ratio of 1.33. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 3.800 SEK is 207.7% above the current price.